Results 61 to 70 of about 1,844 (180)

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]

, 2021
BACKGROUND: Improving symptoms is a primary treatment goal in patients with obstructive hypertrophic cardiomyopathy. Currently available pharmacological options for hypertrophic cardiomyopathy are not disease-specific and are often inadequate or poorly ...
Dolan, C, Elliott, P, Fine, JT, Ho, CY, Jacoby, D, Li, W, Olivotto, J, Reaney, M, Saberi, S, Sehnert, AJ, Spertus, JA   +10 more
core  

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1982-1992, December 2025.
ABSTRACT Aficamten is a next‐in‐class, cardiac myosin inhibitor in development as a potential chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PK) model was developed using data from nine clinical studies to characterize aficamten PK and identify covariates that may alter aficamten exposure ...
Donghong Xu, Hanbin Li, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Polina German, Justin Lutz   +6 more
wiley   +1 more source

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is a selective, allosteric, reversible cardiac myosin inhibitor that has been developed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Peter Chang, Vidya Perera, David H. Salinger, Samira Merali, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amy J. Sehnert, Maria Palmisano, Amit Roy   +10 more
doaj   +1 more source

Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction

Open Heart
Background Hypertrophic cardiomyopathy (HCM) is characterised by abnormal thickening of ventricular myocardium. Left ventricular outflow tract (LVOT) obstruction occurs in up to 70% of patients, causing progressive symptoms, heart failure and mortality ...
Jane Draper, Antonio De Marvao, Robert M Cooper, Gerry Carr-White, Nabeel Sheikh, Rachel Bastiaenen, Yande Kasolo, Jason N Dungu, Edward Burford   +8 more
doaj   +1 more source

New insights into applications of base editor in hereditary disorders

Interdisciplinary Medicine, Volume 3, Issue 6, November 2025.
Abstract Hereditary disorders are a group of diseases caused by genetic mutations or chromosomal variations. Although the incidence of each genetic disorder is relatively low, patients affected by the disease generally experience a range of severe symptoms, including blindness, disability, and even premature death. In addition, the available treatments
Maoping Cai, Linhui Zhang, Liqing Li, Yue Liu, Canbin Lv, Yan Shi, Jianyuan Zhao, Dingwei Ye, Yuanyuan Qu   +8 more
wiley   +1 more source

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, Volume 65, Issue 11, Page 1381-1391, November 2025.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

Two‐Year Results of Percutaneous Endocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy

Catheterization and Cardiovascular Interventions, Volume 106, Issue 4, Page 2763-2769, October 1, 2025.
ABSTRACT Background Hypertrophic obstructive cardiomyopathy (HOCM) is a hereditary myocardial disease. Percutaneous endocardial septal radiofrequency ablation (PESA) is an innovative approach for treating HOCM. Consequently, we present the outcomes of the PESA for HOCM. Methods This study included 20 patients with HOCM who received PESA.
NingNing Zheng, YiYuan Chen, YongBing Fu, Feng Xue, FangFang Zhang, Lin Ling, TingBo Jiang   +6 more
wiley   +1 more source

Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis With High Surgical Risk

JACC: Case Reports
Background: Treatment and accurate assessment of aortic valve stenosis (AS) with concomitant obstructive hypertrophic cardiomyopathy (HCM) prove challenging.
Omar M. Abdelfattah, MD, Robyn Bryde, MD, Kutaiba Nazif, MD, Matthew W. Martinez, MD   +3 more
doaj   +1 more source

Real‐World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children

Clinical and Translational Science, Volume 18, Issue 10, October 2025.
ABSTRACT Pharmacogenomic (PGx) testing is increasingly utilized to guide psychiatric medication selection and dosing, yet real‐world characterizations of test ordering and clinical implications remain understudied. Additionally, the extent to which psychiatry‐focused PGx results inform prescribing beyond mental health medications is unclear. This study
Lusi Zhang, Anthony J. Tholkes, Kaliya C. Jones, Laylia J. Yang, Gretchen K. Sieger, Kathryn R. Cullen, Meredith L. Gunlicks‐Stoessel, Pawel Mroz, Joel F. Farley, Steven G. Johnson, Jeffrey R. Bishop   +10 more
wiley   +1 more source